FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10 EV 323497533 US Express Mail Label Number Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1625

ROBL ET AL.

Examiner: Evelyn Mei Huang

APPLICATION NO: DIVISION OF APPLICATION SERIAL NO.

10/007,407, FILED DECEMBER 4, 2001

FILED: HEREWITH

FOR: HMG-COA REDUCTASE INHIBITORS AND METHOD

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed concurrently with the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 10/007,407 filed December 4, 2001, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000

(609) 252-4336


Date: Tre 24,2003

Respectfully submitted,

Burton Rodney

Attorney for Applicants

Reg. No. 22,076



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ROBL ET AL.

APPLICATION NO: UNKNOWN

FILED: HEREWITH

FOR: HMG-COA REDUCTASE INHIBITORS AND METHOD

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed concurrently with the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-4336

Date: June 6, 2001

Burton Rodney
Attorney for Appli

Attorney for Applicants

Reg. No. 22,076

FORM PTO-1449 (REV. 7-85)

EXAMINER

U.S. DEPARA IT OF COMMERCE PATENT AN LADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use s veral sheets if necessary)

ATTY, DO NO. HX0115 N APPLICATION NO.

APPLICANT ROBL ET AL. **FILING DATE**

Group

U.S. PATENT DOCUMENTS EXAMINER **DOCUMENT NUMBER** DATE NAME CLASS SUBCLASS FILING DATE INITIAL AA 4,906,624 3/6/90 Chacholowski et al 5/15/90 AB 4,925,852 Keeseler et al AC 5,006,530 4/9/91 Angerbauer et al AD 5,169,857 12/8/92 Angerbauer et al AE 5,177,080 1/5/93 Angerbauer et al AF 5,686,433 11/11/97 Robl AG AΗ ΑI AJ AK AL **FOREIGN PATENT DOCUMENTS** TRANSLATION **DOCUMENT NUMBER** DATE **OFFICE** CLASS **SUBCLASS** YES NO **AM** 3/15/89 EP EP 0306929A2 3/15/89 EP AN EP 0307342A2 AO EP 0325129A2 7/26/89 EP П AP EP0325130A2 7/26/89 EP AQ · OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) Robl et al, J. Med. Chem., 34, 2804-2815, 1991. AR AS AT

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in *EXAMINER: conformance and not considered. Includ a copy of this form with the next communication to applicant.

DATE CONSIDERED

CERTIFICATE OF MAILING									
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.									
Burton Rodney Type or print name	Signature	///23/01 Date							

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ROBL ET AL.

APPLICATION NO: 09/875,155

FILED: JUNE 6, 2001

FOR: HMG-COA REDUCTASE INHIBITORS AND METHOD

Assistant Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in a search report in a corresponding PCT International application. Copies of these references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Certificate under 37 C.F.R. §1.97(e)(1)

I, the undersigned attorney, hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-4336

Date: ///28/0/

Burton Rodney

Attorney for Applicants

Reg. No. 22,076

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10							
EL596928075US	12/4/01						
Express Mail Label Number	Date of Deposit						

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ROBL ET AL.

APPLICATION NO: UNKNOWN

FILED: HEREWITH

FOR: HMG-COA REDUCTASE INHIBITORS AND METHOD

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed concurrently with the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 09/875,515 filed June 6, 2001, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000

Date: December 1/2001

Burton Rodney Attorney for Applicants

Reg. No. 22,076 (609) 252-4336

FORM PTO-1449 (REV. 7-85)

EXAMINER

U.S. DEPAR' PATENT ANI NT OF COMMERCE ADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Us several sheets if necessary)

ATTY. DOC HX0115 NP APPLICATION NO. 09/875,155 **APPLICANT** ROBL ET AL. **FILING DATE** JUNE 6, 2001

Gr up

U.S. PATENT DOCUMENTS											
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CL	ASS	SUBCLA	SS	FILING DATE		
	AA	5,753,675	5/19/98	Wattanasin, S.							
	AB										
	AC			·							
	AD										
	AE										
-	AF										
	AG								*******		
	АН										
	Al					Ì					
	AJ										
	AK										
	AL										
FOREIGN PATENT DOCUMENTS											
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBC	CLASS	TRAI	NSLATION NO		
	AM	EP 0491226A	6/24/92	Europe							
	AN	EP 0444533A	9/11/97	Europe							
	AO	EP 0818197A	1/14/98	Europe							
	AP										
	AQ										
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)											
	AR										
	AS										
	АТ										

DATE CONSIDERED

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.